The MEK inhibitor Trametinib, an FDA-approved drug for the treatment of lung cancer, inhibits this downregulation of expression, blocks the conversion of microglia to a pro-tumor phenotype, and inhibits glioma growth (91). Here, MAP2K7 is linked to glioma.